Imidazoylalkyl substituted with a six membered nitrogen containing nitrogen containing heterocyclic ring

- Schering Corporation

Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula 1.0 to a patient in need of such treatment.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A compound of the formula: ##STR63## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H;

(B) R.sup.5 is selected from the group consisting of:
(1) H;
(2) C.sub.1 to C.sub.20 alkyl;
(3) C.sub.3 to C.sub.6 cycloalkyl;
(4) --C(O)OR.sup.7'; wherein R.sup.7' is the same as R.sup.7 defined below except that R.sup.7' is not H;
(5) --C(O)R.sup.7;
(6) --C(O)NR.sup.7 R.sup.8;
(7) allyl;
(8) propargyl; and
(9) --(CH.sub.2).sub.q --R.sup.6, wherein q and R.sup.6 are as defined above, and when q is equal to 1, then R.sup.6 is not OH or SH; and
(C) R.sup.7 and R.sup.8 are each independently selected from the group consisting of: H, C.sub.1 to C.sub.6 alkyl, and C.sub.3 to C.sub.6 cycloalkyl.

2. A compound of the formula: ##STR64## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H; and

(B) R.sup.5 is selected from the group consisting of:
(1) H; and
(2) C.sub.1 to C.sub.6 alkyl.

3. A compound of the formula: ##STR65## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H; and

(B) R.sup.5 is H.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 1.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 2.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 3.

Referenced Cited
U.S. Patent Documents
3491098 January 1970 Archer
4324487 April 13, 1982 Bradshaw
4404382 September 13, 1983 Gall
4404387 September 13, 1983 Gall
4431653 February 14, 1984 Wei
4707487 November 17, 1987 Arrang
4767778 August 30, 1988 Arrang et al.
4925851 May 15, 1990 Houlihan
4935417 June 19, 1990 Pascal et al.
5010075 April 23, 1991 Pascal et al.
5071859 December 10, 1991 Knudsen
5091428 February 25, 1992 Pascal et al.
5290790 March 1, 1994 Arrang
Foreign Patent Documents
0197840 October 1986 EPX
0338939 October 1989 EPX
0372125 June 1990 EPX
Other references
  • West Jr. et al., Journal of Neurochemistry, vol. 55, No. 5, pp. 1612-1616 (1990). Korte et al., Biochemical and Biophysical Research Communications, vol. 168, No. 3, pp. 979-986 (1990). RN 80101-09-3 For CA 96(1): 6760b (1981). Current Neurology, vol. 6, pp. 313-316 (1987). Schunack, CA 80(15): 828o/a (1973).
Patent History
Patent number: 5932596
Type: Grant
Filed: Jun 1, 1995
Date of Patent: Aug 3, 1999
Assignee: Schering Corporation (Kenilworth, NJ)
Inventors: Neng-Yang Shih (North Caldwell, NJ), Michael J. Green (Skillman, NJ)
Primary Examiner: Ceila Chang
Attorney: Henry C. Jeanette
Application Number: 8/457,352
Classifications
Current U.S. Class: The Additional Ring Is A Hetero Ring (514/326); Plural Ring Nitrogens In The Additional Hetero Ring (546/210)
International Classification: A61K 31445; C07D40106;